Follow

Interview with Scandion Oncology

08 October 2020 - 11:32
Interview with Scandion Oncology CSO Nils Brünner during the cancer research day at Penser Bank....
Nasdaq First North GM (Sweden)
Scandion Oncology A/S
Scandion Oncology A/S is a biotechnology company with the mission to address one of the most important challenges in modern oncology - the effective treatment of cancer which has developed resistance towards existing cancer medicine. Its first-in-class lead compound, SCO-101, is an add-on to chemotherapy and is currently in clinical phase I and II studies in cancer patients. The company also has s...
Learn more about company

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More